Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS

NCT00856544 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00856544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00856544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2009
Completion date
January 31, 2011
Enrollment
795 (actual)
Sites
133

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid